Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMPA Receptor Blockade With LY300164 in the Treatment of Parkinson's Disease
NCT00004576Phase 2Completed
- Sponsor
- National Institute of Neurological Disorders and Stroke
- Start
- Feb 2000
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of talampanel in Parkinson's disease (PD), dyskinesia, sponsored by National Institute of Neurological Disorders and Stroke. Started Feb 2000; status: completed.
02
Drugs
talampanel
03
Conditions
Parkinson's disease (PD)dyskinesia
Beyond the preview
Go deeper on NCT00004576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004576.